Jacobio Pharmaceuticals Group Co., Ltd. (1167) AI Stock Analysis

• Market Cap: HK$6.01B
• Dividend Yield: N/A
• Average Volume (3M): 7.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 770.20%
• EPS Growth: 87.27%
• Country: HK
• Employees: 257
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 791,755,070
• 10 Day Avg. Volume: 5,388,349
• 30 Day Avg. Volume: 7,936,853
• PEG Ratio: 0.11
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 5.94
• P/FCF Ratio: -10.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$9.50
• Price Target Upside: 24.51% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$8.00 ▲(4.85% Upside)

The overall stock score is primarily impacted by the company's financial instability, with consistent net losses and poor cash flow metrics. Technical analysis suggests some potential for recovery, but valuation remains weak due to negative earnings. The absence of earnings call insights and corporate events limits additional context.

Positive Factors

Strong Cash Position

A strong cash position provides a liquidity buffer, allowing the company to sustain operations and invest in R&D despite financial challenges.

Collaborative Partnerships

Collaborative partnerships can drive innovation and expand market reach, supporting long-term growth through shared expertise and resources.

Revenue Growth

Substantial revenue growth suggests a rebound in business operations, potentially leading to improved financial stability and market confidence.

Negative Factors

Consistent Net Losses

Ongoing net losses indicate challenges in achieving profitability, which can hinder long-term sustainability and investor confidence.

Negative Cash Flow

Negative cash flow suggests difficulties in generating sufficient cash from operations, potentially limiting the ability to fund growth initiatives.

Declining Equity Base

A declining equity base can signal financial instability, reducing the company's ability to absorb losses and secure financing.

Jacobio Pharmaceuticals Group Co., Ltd. Business Overview & Revenue Model

Company Description

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.

How the Company Makes Money

Jacobio Pharmaceuticals generates revenue through several key streams, including the sale of its proprietary drug products once they receive regulatory approval and are commercialized. The company also engages in collaborative partnerships with other pharmaceutical firms, which may involve licensing agreements, joint ventures, or research collaborations that provide upfront payments, milestone payments based on clinical progress, and royalties on future sales. Additionally, Jacobio may receive funding through grants or investments aimed at supporting its research and development efforts, further contributing to its financial growth.

Jacobio Pharmaceuticals Group Co., Ltd. Financial Statement Overview

Summary

Jacobio Pharmaceuticals Group Co., Ltd. faces significant challenges with consistent net losses and operational inefficiencies impacting profitability and cash flow. While a strong cash position provides some liquidity buffer, declining revenue, negative equity history, and poor cash flow metrics highlight financial instability.

Income Statement

The company has experienced significant volatility in revenue, with a notable decline from 2020 to 2023 and some recovery in 2024. Gross profit margin is positive in the latest year, but net profit margin remains negative due to high operating expenses and consistent net losses. The EBIT and EBITDA margins are also unfavorable, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong cash position relative to debt, resulting in negative net debt, which is a positive indicator of liquidity. However, the equity ratio has decreased over time, and the company has reported negative stockholders' equity in previous years, indicating financial instability. The debt-to-equity ratio is manageable, but the declining equity base is a concern.

Cash Flow

The company has struggled with negative operating cash flow and free cash flow over the years, reflecting operational inefficiencies. The lack of free cash flow growth and negative cash flow from operations are significant concerns, although the company maintains a strong cash reserve.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	201.37M	155.71M	63.52M	95.75M	152.81M	486.29M
Gross Profit	201.37M	155.71M	3.20M	12.63M	12.83M	442.17M
EBITDA	-72.93M	-192.36M	-325.73M	-355.80M	-289.83M	-1.50B
Net Income	-45.65M	-155.71M	-359.12M	-371.86M	-301.19M	-1.51B
Balance Sheet
Total Assets	1.29B	1.36B	1.46B	1.57B	1.72B	1.87B
Cash, Cash Equivalents and Short-Term Investments	1.07B	1.17B	1.15B	1.28B	1.54B	1.63B
Total Debt	143.01M	152.08M	209.91M	147.79M	6.81M	10.65M
Total Liabilities	423.87M	435.99M	387.11M	292.12M	84.75M	81.15M
Stockholders Equity	867.38M	923.18M	1.07B	1.28B	1.64B	1.79B
Cash Flow
Free Cash Flow	99.69M	-86.21M	-402.86M	-308.92M	-158.63M	67.87M
Operating Cash Flow	106.31M	-74.12M	-364.20M	-292.42M	-147.49M	78.83M
Investing Cash Flow	212.53M	256.22M	-48.00M	-686.32M	161.67M	-215.56M
Financing Cash Flow	-4.48M	21.28M	246.28M	-9.85M	109.06M	1.28B

Jacobio Pharmaceuticals Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.63
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1167, the sentiment is Positive. The current price of 7.63 is below the 20-day moving average (MA) of 7.69, above the 50-day MA of 7.46, and above the 200-day MA of 6.65, indicating a neutral trend. The MACD of -0.27 indicates Positive momentum. The RSI at 52.03 is Neutral, neither overbought nor oversold. The STOCH value of 65.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1167.

Jacobio Pharmaceuticals Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	61 Neutral	HK$1.93B	238.10	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1873	51 Neutral	HK$4.10B	22.22	4.45%	―	-8.11%	―
3681	45 Neutral	HK$2.35B	-11.90	-55.33%	―	-100.00%	30.68%
1167	45 Neutral	HK$6.01B	-120.16	-5.08%	―	770.20%	87.27%
2616	42 Neutral	HK$8.41B	-18.58	-95.84%	―	-55.64%	-158.67%
2179	41 Neutral	HK$1.90B	-2.69	-129.05%	―	―	-18.99%

Jacobio Pharmaceuticals Group Co., Ltd. Corporate Events

Jacobio Strikes Up to US$1.9 Billion Global KRAS Inhibitor Deal With AstraZeneca

Jacobio Pharmaceuticals has entered into a global licence and collaboration agreement with AstraZeneca for its pan-KRAS inhibitor JAB-23E73, granting AstraZeneca exclusive rights to develop, register, manufacture and commercialize the drug worldwide outside mainland China, while the two companies will jointly develop and co-commercialize the product in the mainland China market under a shared governance and cost framework. Under the deal, Beijing Jacobio will receive an upfront payment of US$100 million and may earn up to US$1.915 billion in additional development, regulatory and commercial milestone payments plus tiered royalties on net sales, a structure that significantly strengthens Jacobio’s funding and positions it to expand its international partnerships and maximize the scientific and commercial value of its oncology technology platforms as JAB-23E73 advances in trials targeting KRAS-mutant solid tumors such as pancreatic, lung and colorectal cancers.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Secures RMB125 Million to Advance Oncology Pipeline

Jacobio Pharmaceuticals Group Co., Ltd. announced that its subsidiary, Beijing Jacobio, received an upfront payment of RMB125 million from Oceanpine Capital as part of a Capital Increase Agreement and Equity Transfer Agreement. This financial boost is expected to enhance the company’s cash reserves and support the development of its innovative oncology therapies, potentially strengthening its position in the pharmaceutical industry.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio’s KRAS G12C and SHP2 Therapy Shows Promising Results in Clinical Trials

Jacobio Pharmaceuticals Group Co., Ltd. has announced that the Phase I/IIa clinical study results of its KRAS G12C inhibitor glecirasib, combined with the SHP2 inhibitor JAB-3312, have been published in The Lancet Respiratory Medicine. This study, conducted in China with 171 patients, showed promising results with a 71% objective response rate and a 12.2-month median progression-free survival in untreated non-small cell lung cancer patients. The combination therapy, which is chemotherapy-free, is now in Phase III trials and could potentially become the first SHP2-containing combination therapy to gain global approval, positioning Jacobio as a competitive player in the oncology treatment landscape.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Appoints Dr. Andrea Wang-Gillam as Co-CEO to Boost Global Strategy

Jacobio Pharmaceuticals Group Co., Ltd. has announced the appointment of Dr. Andrea Wang-Gillam as Co-Chief Executive Officer, effective November 12, 2025. This strategic move aims to enhance the company’s global strategic deployment and operational efficiency, particularly in overseas markets. Dr. Wang-Gillam brings extensive experience in oncology and international pharmaceutical markets, which is expected to strengthen Jacobio’s international strategy and create greater value for its shareholders.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$9.50 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Unveils Promising Preclinical Data for Pan-KRAS Inhibitor

Jacobio Pharmaceuticals announced the presentation of preclinical data for their pan-KRAS inhibitor, JAB-23E73, at the AACR-NCI-EORTC 2025 conference. The data indicates that JAB-23E73 shows strong antitumor activity and good tolerability in KRAS-driven cancer models, with ongoing Phase I trials in China and the U.S. This advancement could enhance Jacobio’s position in the oncology sector, potentially impacting stakeholders positively if successful.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.

Jacobio Pharmaceuticals Advances Strategic Focus with Capital Increase and Equity Transfer

Jacobio Pharmaceuticals Group Co., Ltd. has announced a capital increase and equity transfer agreement involving its subsidiaries and partners, including Oceanpine Capital. This strategic move allows Jacobio to focus on its core oncology therapies while optimizing capital allocation and enhancing organizational efficiency. The proceeds from the transaction will be used to advance the company’s Pan-KRAS inhibitor and other innovative oncology projects, aligning with its strategic goals and benefiting shareholders.

The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.